Corporate development

Western Forest Products Inc. Announces Release Date of First Quarter 2024 Results and Conference Call Details

Retrieved on: 
Thursday, March 28, 2024
PDT, Senior, Marketing, TSX, Corporate development, EDT

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) first quarter 2024 financial and operating results will be released on Tuesday, May 7, 2024.

Key Points: 
  • VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) first quarter 2024 financial and operating results will be released on Tuesday, May 7, 2024.
  • Western will host its first quarter 2024 analyst conference call on Wednesday, May 8, 2024 at 12:00 p.m. PDT (3:00 p.m. EDT).
  • Steven Hofer, President and Chief Executive Officer, Stephen Williams, Executive Vice President and Chief Financial Officer, Bruce Alexander, Senior Vice President, Sales, Marketing and Manufacturing and Glen Nontell, Vice President, Corporate Development, will discuss the Company’s first quarter 2024 results followed by a question and answer session with the analyst community.
  • To join the conference call, dial:
    Toll-free from Canada and the US: 1-800-952-5114
    To access the instant replay of the call, dial:
    Toll-free from Canada and the US: 1-800-408-3053
    The instant replay will be available until June 8, 2024 at 8:59 p.m. PDT (11:59 p.m. EDT).

Mesirow Names Ketan Shah to Newly Created Chief Strategy Officer Role, Reinforcing Focus on Growth Initiatives

Retrieved on: 
Monday, April 8, 2024
Ketan, Associate, General counsel, RIA, Corporate development, Growth, Acquisition, Kirkland & Ellis, Kirkland, Head, Management

Shah to partner with CEO, Board of Directors and executive leadership team

Key Points: 
  • Shah to partner with CEO, Board of Directors and executive leadership team
    CHICAGO, April 8, 2024 /PRNewswire/ -- Mesirow, an independent, employee-owned financial services firm, today announced the promotion of Ketan Shah to Chief Strategy Officer.
  • In this newly created role, Shah will partner closely with Mesirow's CEO, Board of Directors and leadership team to develop and implement the firm's strategic growth plans.
  • In addition to serving as Chief Strategy Officer, Shah will continue with his existing responsibilities as the firm's General Counsel and will continue to report to Natalie Brown, Mesirow's CEO.
  • "Ketan's promotion to Chief Strategy Officer is a testament to his outstanding contributions and deep understanding of our business," said Natalie Brown , Mesirow CEO.

OpenText Strengthens Leadership Team; Appoints Three Presidents, including Todd Cione as incoming President WW Sales

Retrieved on: 
Monday, April 8, 2024
Information management, Microsoft, OpenText, Growth, Apple, EVP, CFO, Trust, Customer success, Cione, AI, TSX, Teradata, Corporate development, Corporation, Management

Each of Mr. Cione, Mr. Duggan and Ms. Ranganathan will directly report to OpenText CEO & CTO Mark J. Barrenechea.

Key Points: 
  • Each of Mr. Cione, Mr. Duggan and Ms. Ranganathan will directly report to OpenText CEO & CTO Mark J. Barrenechea.
  • He brings to OpenText more than 30 years of experience in global sales at large multi-national technology organizations, including Teradata, Apple, Microsoft, and Oracle.
  • "I believe OpenText's strategy of Information Management, in the cloud, at scale, is a winning strategy," said Todd Cione, President of Worldwide Sales.
  • For full biographical information on Todd Cione, Paul Duggan, and Madhu Ranganathan, as well as the entire OpenText Executive Leadership Team, please visit here .

OpGen Announces Acquisition of Preferred Stock by David Lazar

Retrieved on: 
Monday, March 25, 2024
Common stock, BofA Securities, Doctor of Philosophy, European Investment Bank, EIB, Trustee, Corporate development, Curetis, Corporation

On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.

Key Points: 
  • On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.
  • Each share of Series E Preferred Stock is convertible into 24 shares of the Company’s common stock (“Common Stock”).
  • The conversion of the Series E Preferred Stock into shares of common stock in excess of applicable statutory and regulatory thresholds, including national stock exchange rules, will be subject to receipt of stockholder approval for the issuance of such shares of Common Stock.
  • We believe the transaction also offers future opportunities for OpGen stockholders to participate in possible future strategic transactions under the leadership of David Lazar and the new members of the board.

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Growth, Associated, Horizon Therapeutics, Executive, Patient, Business development, Acquisition, Élan, Inflammation, University College Cork, Commerce, Perrigo, Investment, Corporate development, Autoimmunity, Management

“This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.

Key Points: 
  • “This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.
  • “It is a pleasure to welcome Mike at this critical period of our growth.
  • His experience and expertise defining and advancing corporate strategies along with his proven track record of delivering value-accretive collaborations and transactions strengthen our leadership team and position us for success.
  • Mr. Kelliher began his career in banking, public accounting and corporate finance and holds a Bachelor of Commerce degree from the University College Cork (Ireland).

Nano Dimension Announces Record 2023 Revenue of $56.3 Million and Organic Growth of 29%

Retrieved on: 
Thursday, March 21, 2024
Research, Service provider, Attention, ROI, Senior, RET, Tower Semiconductor, Initiative, AME, Share repurchase, Sale, 3D, Acquisition, G&A, Aviation, Multi, ADS, Record, Nano, Robotics, Annual general meeting, PCB, Vice president, Workforce, Patent, 3D printing, Fraunhofer Society, Marketing, Corporate development, Human, Army, Printing, Video game

WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”), today announced financial results for the fourth quarter and full year ended December 31st, 2023.

Key Points: 
  • Nano Dimension has a breadth of technologies and products assortment, yet narrow and focused span of synergistic vertical markets.
  • It is specifically designed to enable Nano Dimension to become operating income positive in 2025, and potentially cash flow positive earlier.
  • As an example, Q4/2023’s $14.5 million in revenue was 19% higher than the same period in the year before.
  • With close to $56.3 million of revenue, Nano Dimension is the fastest growing of the cohort of publicly traded AM / 3D printing companies (approximately 10-12).

Qlarant Announces Addition to Leadership Team

Retrieved on: 
Wednesday, March 20, 2024
Automation, Cooke, Growth, Research, Acquisition, Business development, CGSO, IBM, Thought, The Advisory Board Company, Marketing, Corporate development, Management

Easton, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Qlarant is proud to announce the addition of Mr. Michael O. Cooke as Chief Strategy and Growth Officer (CGSO).

Key Points: 
  • Easton, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Qlarant is proud to announce the addition of Mr. Michael O. Cooke as Chief Strategy and Growth Officer (CGSO).
  • This is a new position for the nationally-recognized leader in health care quality improvement, program integrity, and technology solutions.
  • “Michael brings extensive experience to Qlarant, and more importantly, is a great fit for what we want to accomplish over the next 10 years.
  • “I am eager to start working with the team to build and expand our capabilities while developing new markets and opportunities.”

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

Retrieved on: 
Wednesday, March 20, 2024
DPT, CDMO, Growth, Chairperson, Wynnefield Capital, University, Laboratory, Head, Senior, Marketing, Syringe, Investment, Annual report, Retirement, Calendar, Corporate development, Fiscal, Management

CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis.

Key Points: 
  • This conclusion was based on an expansive strategic review process, including outreach to and engagement with over 75 buyers, including both strategic buyers and financial sponsors.
  • “The Board of Directors appreciates all of the hard work put into the strategic review process by the Company and its advisors.
  • The Board looks forward to working with the management team to lead the Company’s execution on its strategic plan,” said Craig Barbarosh, Chairman of the Board.
  • With these investments, Lifecore believes it is positioned for substantial growth as its additional aseptic capacity becomes available.

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

Retrieved on: 
Tuesday, March 19, 2024
Growth, Information technology, Central nervous system, General counsel, Warner Chilcott, CNS, Senior, Davis Polk, Therapy, Corporate development, Management

Mr. Halstead is currently serving as Executive Vice President and General Counsel.

Key Points: 
  • Mr. Halstead is currently serving as Executive Vice President and General Counsel.
  • In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation.
  • “Michael is an exceptional leader who has been instrumental in Intra-Cellular Therapies’ strong growth over the last decade,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
  • He joined Intra-Cellular Therapies in 2014 as Senior Vice President and General Counsel and was promoted to Executive Vice President and General Counsel in 2019.

FutureFuel Announces Director Resignation and Appointment of New Director

Retrieved on: 
Monday, March 18, 2024
FF, Olin Corporation, Regulation S-K, Strategic planning, Regulation, Commercial, Biofuel, Security (finance), Death, Northwestern University, Arthur Andersen, Corporate development, Audit committee

Prior to his resignation, Mr. Louvel served on the Audit Committee of the Board.

Key Points: 
  • Prior to his resignation, Mr. Louvel served on the Audit Committee of the Board.
  • Mr. Louvel’s resignation was not the result of any dispute or disagreement with the Company or the Board.
  • He was a Vice President/Senior Director of Monsanto, working for the Chairman and at G D Searle.
  • There are no arrangements between Mr. Greer and any other person pursuant to which he was elected to serve as a director.